Headquartered in Basel, Switzerland, we are a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, our two core business areas.
We are the world’s largest biopharmaceutical company, with truly differentiated medicines in cancer, immunology, infectious diseases, ophthalmology and neuroscience.
Thirty-two medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them antibiotics, anti-malarials and chemotherapy.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
We have been present in Australia for more than 65 years and are represented by our three divisions: Roche Pharmaceuticals; Roche Diagnostics and Roche Diabetes Care.
Our pharmaceutical division employs more than 300 people and is based in the vibrant Barangaroo precinct of Sydney’s CBD. We are dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines and invest around $46 million AUD in local pharmaceutical research and development each year. Australian patients have access to 49 Roche medicines, and we are one of the leading provider of cancer medicines in Australia by sales.
Roche Diagnostics is located at North Ryde and serves customers spanning the entire healthcare spectrum - including hospital and private commercial laboratories, physicians, and patients with conditions requiring them to self-test. Diagnostics allows laboratories to be the reliable partners that healthcare professionals need. It empowers doctors to make the right decisions for their patients at the right time; it allows people to have improved control over their health and wellbeing, and it gives payers and policymakers the confidence that they are investing in the right solutions for patients and the future of healthcare.
Based in North Ryde, Roche Diabetes Care supports people with diabetes in Australia, as well as those at risk to help them achieve more time in their target range and experience true relief from the daily therapy routines. Under the brand Accu-Chek and in collaboration with partners, Roche Diabetes Care creates value by providing integrated solutions to monitor glucose levels, deliver insulin and track as well as contextualize relevant data points for a successful therapy. By establishing a leading open ecosystem, connecting devices, digital solutions, Roche Diabetes Care enables optimal personalised diabetes management and improved therapy outcomes. Roche acquired digital diabetes management platform, mySugr, which now provides Accu-Chek patients with resources to help them manage their condition.
Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visit